Table 1. Baseline characteristics of those retained in the cohort and lost to follow-up among study of HIV discordant couples in rural Yunnan, China, 2009–2011.
| Characteristics | Retained in Cohort N (%) | Lost to Follow-up N (%) | P-value |
| HIV-negative partners at baseline | |||
| Age (years) | |||
| <30 | 233 (28.6) | 80 (27.8) | 0.9380 |
| 30–39 | 338 (41.6) | 123 (42.7) | |
| ≥40 | 242 (29.8) | 85 (29.5) | |
| Gender | |||
| Female | 646 (79.5) | 220 (76.4) | 0.2746 |
| Male | 167 (20.5) | 68 (23.6) | |
| Education | |||
| Illiterate or primary school | 560 (68.9) | 203 (70.5) | 0.6117 |
| Junior/middle or high school | 253 (31.1) | 85 (29.5) | |
| History of any drug use | |||
| No | 787 (96.8) | 279 (96.9) | 0.9516 |
| Yes | 26 (3.2) | 9 (3.2) | |
| History of injecting drug use | |||
| No | 808 (99.4) | 285 (99.0) | 0.4638 |
| Yes | 5 (0.6) | 3 (1.0) | |
| Injecting drug use in past 12 months | |||
| No | 812 (99.9) | 288 (100.0) | 0.5515 |
| Yes | 1 (0.1) | 0 (0.0) | |
| Frequency of sex in past 12 months (times/month) | |||
| No sex | 73 (9.1) | 51 (18.2) | 0.0002 |
| 1–3 | 314 (39.1) | 99 (35.4) | |
| 4–30 | 417 (51.9) | 130 (46.4) | |
| Consistent condom use in past 12 months | |||
| No sex | 73 (9.1) | 51 (18.2) | <0.0001 |
| No | 182 (22.2) | 70 (25.0) | |
| Yes | 549 (68.3) | 159 (56.8) | |
| Syphilis serostatus | |||
| Negative | 752 (98.8) | 253 (98.1) | 0.3677 |
| Positive | 9 (1.2) | 5 (1.9) | |
| HSV-2 serostatus | |||
| Negative | 527 (70.0) | 185 (72.8) | 0.3885 |
| Positive | 226 (30.0) | 69 (27.2) | |
| HIV-positive partners (Index Cases) at baseline | |||
| History of any drug use | |||
| No | 400 (51.9) | 125 (49.8) | 0.5569 |
| Yes | 371 (48.1) | 126 (50.2) | |
| History of injecting drug use | |||
| No | 469 (60.8) | 149 (59.4) | 0.6796 |
| Yes | 302 (39.2) | 102 (40.6) | |
| Injecting drug use in past 12 months | |||
| No | 741 (96.1) | 234 (93.2) | 0.0583 |
| Yes | 30 (3.9) | 17 (6.8) | |
| Syphilis serostatus | |||
| Negative | 706 (96.8) | 233 (98.3) | 0.2339 |
| Positive | 23 (3.2) | 4 (1.7) | |
| HSV-2 serostatus | |||
| Negative | 458 (63.6) | 145 (62.2) | 0.7042 |
| Positive | 262 (36.4) | 88 (37.8) | |
| Antiretroviral treatment | |||
| No | 424 (52.2) | 186 (64.6) | 0.0003 |
| Yes | 389 (47.8) | 102 (35.4) | |
| CD4+ T cell count (cells/µl) | |||
| <200 | 108 (15.3) | 38 (16.5) | 0.9618 |
| 200–349 | 187 (26.4) | 58 (25.2) | |
| 350–499 | 170 (24.0) | 56 (24.4) | |
| ≥500 | 243 (34.3) | 78 (33.9) | |
| Median (IQR) | 399 (244–568) | 396 (262–564) | |
| Plasma HIV viral load (copies/ml) | |||
| <400 | 379 (51.9) | 102 (43.4) | 0.0719 |
| 400–9,999 | 220 (30.1) | 80 (34.0) | |
| 10,000–49,999 | 30 (4.1) | 8 (3.4) | |
| ≥50,000 | 101 (13.8) | 45 (19.2) | |
| Overall | 813 (100.0) | 288 (100.0) | - |
IQR: Inter-quartile range.